TUMOR-IDENTIFYING THERAPEUTICS

In effect, we focus on cancer’s “Achille’s Heel”: the proteins which distinguish tumor cells from normal cells, which can target tumor cells for destruction with extreme sensitivity and precision. As a translational-stage company, we develop our therapeutics with rapid clinical adoption in mind, and in close collaboration with an extensive expert network of world-class academic collaborators.
EXPERT TEAM AND COLLABORATORS
We were founded in 2016 by experts in immuno-oncology and mass-personalized bimolecular engineering. Our team has deep expertise in oncology, manufacturing, regulatory affairs, genomics, bioinformatics, and clinical program development. We collaborate closely with leading U.S. academic research centers.